Your browser is no longer supported. Please, upgrade your browser.
Settings
LXRX Lexicon Pharmaceuticals, Inc. daily Stock Chart
LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own0.30% Shs Outstand105.88M Perf Week8.32%
Market Cap840.70M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float105.50M Perf Month48.41%
Income-121.10M PEG- EPS next Q-0.22 Inst Own- Short Float7.61% Perf Quarter8.77%
Sales62.90M P/S13.37 EPS this Y14.20% Inst Trans-3.02% Short Ratio8.77 Perf Half Y-26.62%
Book/sh-0.28 P/B- EPS next Y-21.40% ROA- Target Price22.00 Perf Year-6.59%
Cash/sh1.77 P/C4.49 EPS next 5Y- ROE- 52W Range4.26 - 13.97 Perf YTD19.58%
Dividend- P/FCF- EPS past 5Y5.80% ROI-39.60% 52W High-43.16% Beta0.70
Dividend %- Quick Ratio2.80 Sales past 5Y142.70% Gross Margin96.00% 52W Low86.38% ATR0.49
Employees174 Current Ratio2.90 Sales Q/Q-88.00% Oper. Margin- RSI (14)69.70 Volatility6.83% 7.88%
OptionableYes Debt/Eq- EPS Q/Q71.60% Profit Margin- Rel Volume1.47 Prev Close7.74
ShortableYes LT Debt/Eq- EarningsFeb 28 BMO Payout- Avg Volume915.77K Price7.94
Recom2.30 SMA2019.90% SMA5031.38% SMA200-12.98% Volume1,350,744 Change2.58%
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Aug-19-14Downgrade Gabelli & Co Buy → Hold
Jun-26-12Reiterated Stifel Nicolaus Buy $3 → $4
Apr-26-11Initiated Wedbush Outperform $3
Oct-29-08Downgrade Piper Jaffray Neutral → Sell
Mar-07-08Downgrade Piper Jaffray Buy → Neutral
Oct-31-07Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $5
Aug-07-07Reiterated Punk, Ziegel & Co Buy $24 → $7
Mar-21-19 03:00PM  Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
Mar-20-19 02:44PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact the Firm GlobeNewswire
10:38AM  GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder ACCESSWIRE
07:53AM  Edited Transcript of LXRX earnings conference call or presentation 13-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
Mar-19-19 07:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
04:25PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm Business Wire
Mar-18-19 10:36AM  GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action ACCESSWIRE
07:25AM  Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study Zacks
Mar-15-19 03:00PM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019 GlobeNewswire
10:39AM  Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer GlobeNewswire
07:48AM  Lexicon Pharmaceuticals Inc (LXRX) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-14-19 08:57PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire -6.74%
Mar-13-19 01:49PM  Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript Motley Fool +9.62%
08:15AM  Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:22AM  Lexicon: 4Q Earnings Snapshot Associated Press
07:00AM  Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update GlobeNewswire
06:00AM  Lexicon Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-12-19 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
10:32AM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Stockholders of Class Action & Deadline: April 1, 2019 ACCESSWIRE
08:52AM  Do Options Traders Know Something About Lexicon Pharmaceuticals (LXRX) Stock We Don't? Zacks
Mar-11-19 04:00PM  Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019 GlobeNewswire +5.80%
10:31AM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action & Deadline: April 1, 2019 ACCESSWIRE
07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Mar-08-19 10:15AM  Zacks.com featured highlights include: Lexicon, Medtronic and NetApp Zacks
Mar-07-19 07:24PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire
06:20PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm GlobeNewswire
02:09PM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019 GlobeNewswire
07:52AM  3 Stocks That Flaunt Solid Earnings Acceleration Zacks
Mar-05-19 10:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
10:25AM  STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) ACCESSWIRE
09:00AM  Deadline in Lawsuit for Investors in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced by Shareholders Foundation GlobeNewswire
Mar-04-19 12:04PM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Deadline: April 1, 2019 ACCESSWIRE
10:25AM  INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) ACCESSWIRE
Mar-03-19 06:04PM  Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Deadline: April 1, 2019 ACCESSWIRE
10:24AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) ACCESSWIRE
Mar-01-19 12:16PM  Here's Why Lexicon Pharmaceuticals Jumped as Much as 26.9% Today Motley Fool +28.01%
08:02AM  Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes GlobeNewswire
08:00AM  CHMP Recommends Zynquista (Sotagliflozin) for the Treatment of Adults With Type 1 Diabetes GlobeNewswire
Feb-28-19 05:26PM  Lexicon Pharmaceuticals Announces Poster Presentations at the 16th Annual ENETS Conference GlobeNewswire
03:18PM  Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action & Deadline: April 1, 2019 ACCESSWIRE
02:39PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire
12:18PM  Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Deadline: April 1, 2019 ACCESSWIRE
10:29AM  VALE, LXRX & SVXY: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action ACCESSWIRE
Feb-27-19 03:17PM  Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:17PM  Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds Stockholders of Class Action & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:29AM  VALE, LXRX & SVXY: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action ACCESSWIRE
Feb-26-19 07:44PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX PR Newswire
03:20PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
02:16PM  Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:16PM  Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:28AM  VALE, LXRX & SVXY ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action ACCESSWIRE
Feb-25-19 04:34PM  INVESTOR ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Deadline: April 1, 2019 ACCESSWIRE
12:34PM  INVESTOR ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:27AM  VALE, LXRX & SVXY INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action ACCESSWIRE
Feb-24-19 02:33PM  INVESTOR ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:27AM  VALE, LXRX & SVXY SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action ACCESSWIRE
Feb-22-19 03:11PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:11PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
09:57AM  Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
Feb-21-19 05:09PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire
03:11PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:10PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:31AM  Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know Zacks
09:57AM  Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
07:20AM  Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-20-19 03:09PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:09PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
09:56AM  Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
Feb-19-19 03:08PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:08PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
09:56AM  Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
Feb-17-19 02:00PM  3 Top Diabetes Stocks to Watch in February Motley Fool
11:16AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX ACCESSWIRE
Feb-15-19 02:11PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:11PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:35AM  Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
Feb-14-19 04:12PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX GlobeNewswire
01:39PM  Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc. PR Newswire
12:00PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Vale S.A. (VALE), Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) GlobeNewswire
Feb-13-19 11:40AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
08:15AM  New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-12-19 06:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
Feb-11-19 12:39PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:22AM  Here's Why Lexicon Pharmaceuticals Lost 28.8% in January Motley Fool
Feb-08-19 03:31PM  RM LAW Announces Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc. PR Newswire
Feb-07-19 05:36PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE), Lexicon Pharmaceuticals, Inc. (LXRX) & ProShares Short VIX Short-Term Futures ETF (SVXY) GlobeNewswire
Feb-06-19 11:47AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Feb-05-19 11:47AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Feb-04-19 11:45AM  Lawsuit for Investors in Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced by Shareholders Foundation ACCESSWIRE
Feb-03-19 09:23AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX ACCESSWIRE
Feb-01-19 11:24AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Jan-31-19 07:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE +7.26%
07:40AM  Research Report Identifies Knight-Swift Transportation, Alteryx, Lexicon Pharmaceuticals, Procter & Gamble, MicroStrategy, and SMART SAND INC with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-30-19 06:07PM  LEXICON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm PR Newswire
05:54PM  Robbins Arroyo LLP: Lexicon Pharmaceuticals, Inc. (LXRX) Misled Shareholders According to a Recently Filed Class Action Business Wire
11:24AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Jan-29-19 06:14PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc. Business Wire
04:42PM  About to Buy Penny Stocks? Look at These 3 Companies First Motley Fool
02:31PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 GlobeNewswire
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Invus Public Equities, L.P.DirectorJun 28Buy12.4557,724718,9353,516,214Jun 29 04:23 PM
Invus Public Equities, L.P.DirectorJun 27Buy12.54125,1141,568,4423,458,490Jun 29 04:23 PM
Invus Public Equities, L.P.DirectorJun 25Buy12.95228,2642,955,0833,333,376Jun 26 05:32 PM
Invus Public Equities, L.P.DirectorJun 22Buy13.3625,461340,0903,105,112Jun 26 05:32 PM
Invus Public Equities, L.P.DirectorJun 21Buy13.2751,600684,6133,079,651Jun 21 05:55 PM
Invus Public Equities, L.P.DirectorJun 20Buy13.2812,391164,6133,028,051Jun 21 05:55 PM
Invus Public Equities, L.P.DirectorJun 19Buy13.458,982120,8193,015,660Jun 21 05:55 PM
Invus Public Equities, L.P.DirectorJun 18Buy13.0636,584477,9373,006,678Jun 18 06:56 PM
Invus Public Equities, L.P.DirectorJun 14Buy12.669,200116,4622,970,094Jun 18 06:56 PM
Invus Public Equities, L.P.DirectorJun 12Buy12.83107,0231,373,2442,960,894Jun 12 06:10 PM
Invus Public Equities, L.P.DirectorJun 11Buy12.7598,6261,257,4522,853,871Jun 12 06:10 PM
Tessmer James FVP, Finance & AccountingJun 08Option Exercise10.1510,000101,50035,643Jun 12 04:37 PM
Invus Public Equities, L.P.DirectorJun 08Buy12.8929,747383,4272,755,245Jun 12 06:10 PM
Tessmer James FVP, Finance & AccountingJun 08Sale12.9110,000129,07625,643Jun 12 04:37 PM
Invus Public Equities, L.P.DirectorJun 07Buy12.9357,439742,5082,725,498Jun 07 07:37 PM
Invus Public Equities, L.P.DirectorJun 06Buy12.5895,0791,196,3702,668,059Jun 07 07:37 PM
Invus Public Equities, L.P.DirectorJun 05Buy12.45173,1212,156,1872,572,980Jun 07 07:37 PM
Invus Public Equities, L.P.DirectorJun 04Buy12.24121,8031,490,5762,399,859Jun 04 05:31 PM
Invus Public Equities, L.P.DirectorJun 01Buy12.22147,3391,800,0412,278,056Jun 04 05:31 PM
Invus Public Equities, L.P.DirectorMay 31Buy11.62147,3391,712,0502,130,717Jun 04 05:31 PM
Invus Public Equities, L.P.DirectorMay 30Buy10.32147,3391,521,0251,983,378May 30 08:53 PM
Invus Public Equities, L.P.DirectorMay 29Buy9.84147,3391,450,4201,836,039May 30 08:53 PM
Invus Public Equities, L.P.DirectorMay 25Buy9.62138,7001,334,9741,688,700May 30 08:53 PM
Santini Alexander AEVP and CCOMay 23Buy9.787457,2865,297May 25 04:43 PM